People
Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases
One of the key takeaways from BIO-Europe Spring 2020 was that there is a keen need for greater collaboration and communications among the biotech community, government, non-governmental organizations and the public.
Troubled Unum Therapeutics announced its fourth quarter and full-year financial report yesterday. Among the news was that it is considering seemingly every possible strategic option, including a sale or merger.
A summary of daily biopharma industry news. Please check out stories that are trending on March 26, 2020.
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
“These kinds of situations remind people how important diagnostics are,” Hawkins told BioSpace in an interview.
Kallyope Chief Executive Officer Nancy Thornberry said the company’s journey to becoming a “first-mover in the gut-brain axis space” is coming to fruition.
Rocket Pharmaceuticals CEO Gaurav Shah said the remote-working policies that have resulted from the global COVID-19 pandemic have created a challenging time for the pharmaceutical industry, as well as the rest of the global community, but believes a silver lining will be forthcoming.
To combat the growing number of cases, the state is pulling out the stops in testing the use of antibodies from the plasma of recovered COVID-19 patients.
“The industry is increasing capacities, but at the same time infection rates are even increasing faster,” said Roche CEO Severin Schwan. “At the moment, capacities are limited. That is why we have to prioritize testing to higher risk patients.”
PRESS RELEASES